News & Views
Diagnostics Company Opens in Berlin
Apr 05 2011
Astra Biotech GmbH, Berlin, Germany is a new company whose core focus is the development of innovative diagnostics for the identification of an individual’s predisposition to disease, offering a portfolio of assays in areas such as allergies, genetically associated disorders, hormonal dysfunctions, and others.
Key targets so far are for osteoporosis, a condition which affects over 75 million people worldwide and thrombosis, a major fatal disease in developed countries. Other diagnostic kits include one for the determination of an individual’s susceptibility or resistance to oral anticoagulants as well as niche diseases. A new array technology for improved hybridisation will also become available shortly said the company.
Alexandra Ghica-Cantacuzino, Head of International Sales & Marketing at Astra Biotech GmbH, said: “Our contribution is to optimise patient healthcare by early diagnosis of potential risks to individuals though innovative assays. In Astra Biotech we believe laboratories must understand patient needs and be more specific in their approach to the identification of risk factors so that early intervention helps to minimise any long term effects of a disease. Our target is to continue to assist clinicians, doctors, hospital staff and medical oriented laboratories to improve overall healthcare standards.“
As part of their expansion program Astra Biotech GmbH are now looking to strengthen their distribution channels in Europe and Asia plus are looking for possible OEM manufacturing opportunities for future products.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria